PolyPeptide Group AG

SWX:PPGN Stock Report

Market Cap: CHF 976.5m

PolyPeptide Group Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PPGN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,455,5064.41%
Institutions5,783,48017.5%
General Public7,170,05821.7%
Private Companies18,582,40656.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 77.87% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
56.3%
Draupnir Holding B.V.
18,582,406CHF 550.0m0%no data
5.02%
Premier Fund Managers Ltd.
1,655,153CHF 49.0m-3.34%0.82%
3.33%
Rudolf Maag
1,100,000CHF 32.6m0%no data
3.16%
Swisscanto Asset Management Ltd.
1,043,101CHF 30.9m0%0.36%
3.01%
Newtyn Management, LLC
993,573CHF 29.4m0%3.22%
1.61%
The Vanguard Group, Inc.
530,535CHF 15.7m-0.01%no data
0.93%
HBM Partners Ltd.
308,000CHF 9.1m0%0.9%
0.82%
BlackRock, Inc.
269,982CHF 8.0m0%no data
0.69%
Juan Gonzalez
227,842CHF 6.7m0%no data
0.5%
A&G Fondos Sgiic S.A
165,486CHF 4.9m0%1.64%
0.48%
American Century Investment Management Inc
157,042CHF 4.6m171%no data
0.3%
Dimensional Fund Advisors LP
98,212CHF 2.9m12.9%no data
0.29%
ZKB Asset Management
94,660CHF 2.8m0%0.01%
0.24%
Zürcher Kantonalbank
79,189CHF 2.3m0%0.02%
0.16%
Parametric SAS
53,068CHF 1.6m0%0.08%
0.15%
Schroder Investment Management Limited
50,166CHF 1.5m0%no data
0.14%
Lombard Odier Asset Management (Switzerland) SA
47,610CHF 1.4m0%0.03%
0.13%
State Street Global Advisors, Inc.
41,625CHF 1.2m2.37%no data
0.097%
Deka Investment GmbH
32,100CHF 950.2k0%no data
0.093%
Klaus Wilden
30,690CHF 908.4k0%no data
0.092%
Deutsche Asset & Wealth Management
30,244CHF 895.2k0%no data
0.086%
Charles Schwab Investment Management, Inc.
28,249CHF 836.2k-0.52%no data
0.078%
Jane Salik
25,882CHF 766.1k0%no data
0.072%
Valiant Bank AG
23,715CHF 701.9k0%0.07%
0.067%
Philippe Weber
22,071CHF 653.3k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/22 07:52
End of Day Share Price 2026/01/22 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PolyPeptide Group AG is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Markus MayerBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research